Scott Liu

Founder, Chairman & CEO
HanchorBio Inc.
​

Dr. Scott Liu is the Founder, Chairman & CEO of HanchorBio, bringing over three decades of extensive experience in the biopharmaceutical industry. He earned his Ph.D. in Biology from Purdue University and completed his postdoctoral research in the Department of Biology at Stanford University. Throughout his distinguished career, Dr. Liu has specialized in biologics R&D, CMC, quality operations, and regulatory affairs, having held senior leadership positions at global pharmaceutical companies such as Amgen and Bristol Myers Squibb. As President and CEO of Henlius for more than 11 years, he successfully led integrated development, regulatory strategy, and commercialization efforts that resulted in multiple global approvals of biosimilars and innovative antibody drugs, including Zercepac® (biosimilar to Herceptin) and Hanlikang® (biosimilar to Rituxan), across China, the EU, UK, Australia, and the U.S. Under his leadership, Henlius completed a landmark IPO in Hong Kong, achieving a valuation exceeding USD 3 billion. In late 2020, Dr. Liu founded HanchorBio with the mission to advance next-generation biologics through proprietary fusion protein platforms, aiming to address critical needs in oncology and immune-related diseases. His outstanding contributions to the field have earned him numerous recognitions, such as being named one of The Silicon Review’s 30 Best CEOs of the Year. Dr. Liu continues to dedicate his expertise to driving innovation and delivering high-quality biologics that improve patient outcomes worldwide.​

Speech title & Synopsis

Company Profile

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TWO), a global biotechnology company specializing in immuno-oncology, is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development, aiming to rewrite cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: https://www.hanchorbio.com/